Effects of vitamin C on intracoronary L-arginine dependent coronary vasodilatation in patients with stable angina

D Toussoulis, C Xenakis, C Tentolouris, G Davies, C Antoniades, T Crane, C Stefanadis

Objective: To assess the effects of intravenous vitamin C administration on the vasomotor responses to intracoronary L-arginine infusion in epicardial coronary arteries.

Methods: 28 patients with coronary artery disease and stable angina were enrolled in the study. Eight patients received intravenous infusions of 150 μmol/min L-arginine before and after intravenous infusion of vitamin C, 10 patients received intravenous infusions of 150 μmol/min L-arginine before and after intraarterial infusion of normal saline, and 10 patients received intraarterial normal saline before and after intravenous infusion of vitamin C. The diameter of proximal and distal coronary artery segments was measured by quantitative angiography.

Results: Infusion of L-arginine caused significant dilatation of both proximal (4.87 (0.96)%, p < 0.01 v normal saline) and distal (6.33 (1.38)%, p < 0.01 v normal saline) coronary segments. Co-infusion of vitamin C and L-arginine dilatated proximal coronary segments by 8.68 (1.40)% (p < 0.01 v normal saline, p < 0.01 v L-arginine) and distal segments by 13.07 (2.15)% (p < 0.01 v normal saline, p < 0.01 v L-arginine). Intravenous infusion of vitamin C caused a borderline increase in proximal and distal coronary segment diameters (1.93 (0.76)%% and 2.09 (1.28)%, respectively, not significant).

Conclusions: L-Arginine dependent coronary segment vasodilatation was augmented by the antioxidant vitamin C in patients with coronary artery disease. Thus, vitamin C may have beneficial effects on nitric oxide bioavailability induced by l-arginine.

Coronary vasodilatation in patients with stable angina protected against ischaemia-reperfusion injury.13

Nitrergic nitric oxide is synthesised from the amino acid L-arginine by a family of enzymes through the L-arginine–nitric oxide pathway.1 L-Arginine is the substrate for the production of nitric oxide synthase.

It has been shown that L-arginine administration improves endothelium dependent vasodilatation in patients with risk factors for atherosclerosis, such as hypercholesterolaemia,4 smoking,1 aging,1 and hypertension1 in patients with coronary artery disease2–4 (including dilatation of coronary stenoses),5 microvascular angina pectoris,10 and peripheral arterial disease.6 In animal models, L-arginine has improved endothelial dysfunction after coronary angioplasty2 and protected against ischaemia–reperfusion injury.1

Increased oxidative stress has been implicated as a potential mechanism for abnormal endothelial vasomotor function14 and inactivation of nitric oxide.15 Vitamin C is the main water soluble antioxidant in human plasma14 and it has been shown to reverse nitric oxide dependent endothelial dysfunction in patients with risk factors for atherosclerosis, including hypercholesterolaemia,15 smoking,16 hypertension,17 diabetes,18 and hyperhomocysteaemia,19 as well as in patients with atherosclerosis and coronary artery disease.20 It effectively scavenges superoxide and other reactive oxygen species, thus playing an important part in the regulation of intracellular redox state through its interaction with glutathione.21 Whether administration of combined administration of vitamin C and L-arginine can lead to additional improvement of endothelial function in patients with atherosclerosis has not been investigated. We therefore examined the effects of intravenous vitamin C infusion on the response of the epicardial segments to L-arginine in patients with coronary artery disease and stable angina.

METHODS

Patients

The study population consisted of 28 patients (19 men, nine women) with chronic stable angina, coronary artery disease, and a positive treadmill exercise test (≥ 0.1 mV ST segment depression) at between 5–7 metabolic equivalents with the modified Bruce protocol. Patients were excluded from the study if they had diabetes mellitus, history of coronary spasm, recent myocardial infarction (< 6 months), left ventricular hypertrophy (on echocardiography), three vessel coronary artery disease, left ventricular dysfunction (left ventricular ejection fraction < 50%), or valvar heart disease. Table 1 presents patients’ baseline characteristics. The protocol was approved by the research ethics committee and each patient gave written and informed consent. The investigation conforms with the principles outlined in the Declaration of Helsinki.

Study protocol

Antianginal medication was stopped 48 hours before the study. Patients were allowed to use sublingual glyceryl trinitrate as necessary, but no study was performed within three hours of its administration. After diagnostic coronary angiography, an optimal radiographic projection was selected and kept constant for subsequent angiograms. The artery studied was chosen to comply with the research ethics committee’s requirements that coronary stenoses > 70% be avoided.

Patients were divided into one main group and two control groups, with 8–10 patients constituting each group (table 1). Two ECG leads were monitored continuously throughout the study. All infusions were administered into the coronary artery through a 7 French Judkin angioplasty guiding catheter. In the main group (group A: six men, two women, mean (SEM) age 59 (3.3) years) patients received an intracoronary infusion of 0.9% saline (2 ml/min) for two minutes, followed by an intracoronary infusion of 150 μmol/min of L-arginine for eight minutes, followed by a seven
A minute intravenous infusion of vitamin C (25 mg/min) and an eight minute combined infusion of intravenous vitamin C and intracoronary 150 μmol/min of L-arginine. Group B patients (seven men, three women, mean (SEM) age 57 (2.6) years) underwent the same protocol with the replacement of vitamin C with normal saline. Group C patients (six men, four women, mean (SEM) age 56 (2.2) years) received an intracoronary infusion of 0.9% saline (2 ml/min) for two minutes followed by a seven minute intravenous infusion of vitamin C (25 mg/min) and an eight minute combined infusion of intravenous vitamin C and intracoronary saline.

Lastly, an intracoronary bolus dose of glyceryl trinitrate (250 μg) was administered to patients in all three groups. The distribution of risk factors for atherosclerosis (such as smoking, hypertension, lipid concentrations, or diabetes mellitus) did not differ between the groups (table 1). Antianginal medication (β blockers, aspirin, nitrates, statins, and angiotensin converting enzyme inhibitors) was similar in the three groups of patients. In a preliminary study of five patients we measured plasma concentration of vitamin C. After intravenous vitamin C administration serum vitamin C concentrations rose significantly from 41.8 (6.8) μmol/l to 120.2 (10.6) μmol/l (p < 0.05). This vitamin C concentration has been shown to protect human plasma from free radical mediated lipid peroxidation and to improve endothelium dependent vasodilatation in patients with hypercholeolaemia, in chronic smokers, and in patients with diabetes mellitus. Vitamin C concentrations were measured by high performance liquid chromatography after deproteinisation with 2% sulphur salicylic acid. Femoral arterial pressure and heart rate were recorded before and after L-arginine or L-arginine and vitamin C infusions and two minutes after glyceryl trinitrate administration. Angiography was performed (fig 1) with a hand injection of 6–8 ml non-ionic contrast medium. Before each angiogram, the catheter was emptied to avoid bolus administration of the infusate.

### Quantitative coronary angiography

The arterial segments in each frame were analysed blindly in random order by quantitative computerised analysis with an automated edge contour detection analysis system (CAAS version 2V2; Pie Data Medical, Maastricht, the Netherlands). End diastolic frames from each arteriogram were selected for analysis. The angiographic catheter was used as a scaling device and this, together with pincushion distortion correction, allowed the diameters to be recorded as absolute values (expressed in millimetres). Special care was taken to avoid overlapping of coronary segments. The diameter of angiographically normal proximal and distal segments was recorded as follows: the proximal left anterior descending coronary artery diameter was measured just beyond the origin of the artery and the distal diameter was measured just distal to the second diagonal branch; the proximal left circumflex coronary artery diameter was measured just beyond the origin of the artery and the distal diameter just beyond the origin of the second obtuse marginal branch; and the proximal right coronary artery diameter was measured just beyond the origin of the artery and the distal diameter just beyond the posterior descending branch. Relatively straight coronary segments were preselected. Two proximal segments (one in the left circumflex coronary artery, another in the left anterior descending coronary artery) and two distal segments were usually selected for analysis from each left coronary arteriogram.

### Table 1 Clinical characteristics of the patients

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Group A: l-arg + vit C (n = 8)</th>
<th>Group B: l-arg (n = 10)</th>
<th>Group C: vit C (n = 10)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men/women</td>
<td>6/2</td>
<td>7/3</td>
<td>6/4</td>
</tr>
<tr>
<td>Age (years)</td>
<td>59 (3.3)</td>
<td>57 (2.6)</td>
<td>56 (2.2)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Dyslipidaemia</td>
<td>6</td>
<td>3</td>
<td>7</td>
</tr>
<tr>
<td>Smoking</td>
<td>5</td>
<td>4</td>
<td>7</td>
</tr>
<tr>
<td>Hypertension</td>
<td>4</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>History of MI</td>
<td>2</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Extent of CAD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 vessel</td>
<td>6</td>
<td>7</td>
<td>8</td>
</tr>
<tr>
<td>2 vessel</td>
<td>2</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Cholesterol (mmol/l)</td>
<td>6.10 (0.36)</td>
<td>5.08 (0.64)</td>
<td>6.50 (0.43)</td>
</tr>
<tr>
<td>Triglycerides (mmol/l)</td>
<td>1.52 (0.14)</td>
<td>1.58 (0.16)</td>
<td>1.77 (0.13)</td>
</tr>
</tbody>
</table>

Values expressed as mean (SEM) or number.

CAD, coronary artery disease; l-arg, L-arginine; MI, myocardial infarction; vit C, vitamin C.

There were no significant differences between the three groups.

---

Figure 1 Study protocol for the three groups of patients (A, B, and C) showing timing of angiography (Ang). GTN, glyceryl trinitrate; ic, intracoronary infusion; iv, intravenous infusion; NS, normal saline.
Two independent observers analysed the coronary arteriograms quantitatively and blindly re-analysed the films at a remote time for reproducibility of the method. Intra- and interobserver variabilities were non-significant (analysis of variance $F = 0.3$, $p = 0.75$).

**Statistical analysis**

For descriptive purposes data are expressed as mean (SEM). Analysis of variance for repeated measures was used to compare serial changes in heart rate and blood pressure. To test for differences in baseline values and percentage changes of proximal and distal segments within groups, the Friedman test and Wilcoxon sign rank test for repeated measures were applied: for differences in baseline values and percentage changes of proximal and distal segments between groups, the Kruskal-Wallis test and Mann-Whitney test were applied. A probability value of $p < 0.05$ (two tailed) was considered to indicate significance.

**RESULTS**

**Clinical characteristics**

During the L-arginine infusion the mean (SEM) heart rate ($65 (3.4)$ vs $69 (2.7)$ beats/min before and after, respectively, not significant) and systolic blood pressure ($136 (9) vs 133 (8)$ mm Hg before and after, respectively, not significant) remained unchanged. Similarly, after vitamin C infusion mean (SEM) heart rate ($66 (3.0)$ vs $67 (3.0)$ beats/min before and after, respectively, not significant) and systolic blood pressure ($136 (4)$ vs $135 (5)$ mm Hg before and after, respectively, not significant) did not differ.

**Changes in epicardial coronary arteries**

After saline infusion the luminal diameter of the proximal and distal segments of the epicardial coronary arteries did not change significantly in all groups (table 2).

**Group A**

The percentage increase in mean luminal diameter of the angiographically normal proximal ($p < 0.01$ vs normal saline) and distal ($p < 0.01$ vs normal saline) segments was significant after L-arginine administration (table 2, fig 2). With the co-infusion of vitamin C and L-arginine the diameter further increased significantly in proximal segments ($p < 0.01$ vs L-arginine) and distal segments ($p < 0.01$ vs L-arginine). The dilatation was significantly greater ($p < 0.05$) in distal than in proximal segments (fig 2). Nitrate infusion caused significant vasodilatation ($p < 0.01$) in both proximal and distal segments (table 2, fig 2).

**Group B**

The percentage increase in mean luminal diameter of the proximal ($p < 0.01$ vs normal saline) and distal ($p < 0.05$ vs normal saline) was significant after L-arginine administration (table 2, fig 2). The combined infusion of L-arginine during saline infusion did not further increase the percentage change of the luminal diameter in proximal ($p = 0.758$ vs L-arginine) and distal ($p = 0.365$ vs L-arginine) segments. Distal segments dilated less ($p < 0.05$) than in group A (fig 2). Nitrate infusion caused significant vasodilatation ($p < 0.01$) in both proximal and distal segments (table 2, fig 2). The response to nitrate infusion was similar in the three groups irrespective of vitamin C infusion both in the proximal and in the distal segments.

**DISCUSSION**

Our results showed that L-arginine significantly dilated epicardial coronary arterial segments in patients with atherosclerosis. The co-administration of L-arginine and antioxidant vitamin C significantly augmented this effect, whereas infusion of vitamin C alone caused only borderline dilatation. These findings indicate that vitamin C may increase nitric oxide availability induced by L-arginine administration.

**Endothelial dysfunction and the L-arginine-nitric oxide pathway**

L-Arginine is the substrate for nitric oxide production and has been shown to reduce vascular tone. The mechanism by which it exerts its vasodilator effects is controversial, but

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Effects of intracoronary infusion of L-arginine, vitamin C, combined L-arginine and vitamin C, and nitrates on proximal and distal coronary segments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infusion</td>
<td>Diameter (mm)</td>
</tr>
<tr>
<td><strong>Proximal segment</strong></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>3.02 (0.12)</td>
</tr>
<tr>
<td>NS</td>
<td>3.04 (0.12)</td>
</tr>
<tr>
<td>L-arginine</td>
<td>3.16 (0.13)</td>
</tr>
<tr>
<td>L-arg + NS</td>
<td>3.27 (0.12)</td>
</tr>
<tr>
<td>Vitamin C + NS</td>
<td>3.59 (0.12)</td>
</tr>
<tr>
<td>L-arg + vitamin C</td>
<td>3.85 (0.12)</td>
</tr>
<tr>
<td>Nitrates</td>
<td></td>
</tr>
<tr>
<td><strong>Distal segment</strong></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>1.66 (0.09)</td>
</tr>
<tr>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>L-arginine</td>
<td>1.76 (0.10)</td>
</tr>
<tr>
<td>L-arg + NS</td>
<td></td>
</tr>
<tr>
<td>Vitamin C + NS</td>
<td></td>
</tr>
<tr>
<td>L-arg + vitamin C</td>
<td>1.87 (0.10)</td>
</tr>
</tbody>
</table>

Values are expressed as mean (SEM).

$p < 0.05$, $p < 0.01$ versus baseline; $p < 0.01$ versus L-arginine.

NS, normal saline.
stimulation of the L-arginine-nitric oxide synthase (NOS)-
-B, vitamin C, and L-arginine, respectively. 

Endothelial dysfunction may be partially attributed to L-
arginine deficiency or the presence of L-arginine endogenous
inhibitors such as asymmetric dimethylarginine.27

Effects of vitamin C on L-arginine-nitric oxide pathway
The present study showed that the antioxidant vitamin C
increased nitric oxide availability induced by L-arginine
administration in epicardial coronary arteries. Increased
oxidative stress is known to be a potential mechanism for
abnormal endothelial vasomotor function16 and inactivation
of nitric oxide.17 Nitric oxide is inactivated by two basic
mechanisms. Firstly, nitric oxide reacts with reactive oxygen
species. Superoxide radicals inactivate nitric oxide, leading to
the formation of peroxynitrite—a powerful pro-oxidant that
in high concentrations is toxic to cellular proteins and
lipids.28 The amount of peroxynitrite production depends on
the ratio of superoxide to nitric oxide.29 The second
mechanism involves oxidised low density lipoprotein (LDL),
which can also react directly with and inactivate nitric
oxide.29 Oxidised LDL may interfere with signal transduction
and agonist receptor dependent stimulation of NOS activity
and with activation of guanylyl cyclase.30 Furthermore,
oxidised LDL may induce a decreased uptake and local
depletion of L-arginine, uncouple NOS, and potentially
decrease production of nitric oxide.31 In the absence of
sufficient concentrations of arginine or tetrahydrobiopterin,
NOS itself can be a source of superoxide overproduction.32
In addition a competitive inhibition of nitric oxide synthesis
through accumulation of factors such as asymmetric
dimethylarginine may not be excluded.33

Vitamin C effectively inhibits the reaction of nitric oxide
with superoxide only at very high concentrations, which in
vivo are potentially achievable either in extracellular fluids by
vitamin C infusion or in the intracellular milieu.34 Vitamin C
increases the availability of tetrahydrobiopterin or the affinity
of endothelial NOS (eNOS) for tetrahydrobiopterin and
maintains high intracellular concentrations of glutathione
primarily by a sparing effect, which may enhance the
synthesis or increase the stabilisation of nitric oxide through
formation of S-nitrosothiols.23 35 Vitamin C also exerts LDL
specific antioxidant action by preventing its oxidation or by
regenerating LDL associated α tocopherol, thereby inhibiting
its pro-oxidant action.31

Thus, a balance between variations in eNOS protein
concentrations, regulation of eNOS, and interaction of nitric
oxide with superoxide controls the bioactivity of endothelium
derived nitric oxide. The concentrations of L-arginine substrate
and tetrahydrobiopterin, antioxidant enzymes such as glut-
athione, and other antioxidants such as vitamin C and α
tocopherol may participate in this regulation.30 The main
finding of the present study—that co-administration of vitamin
C increased L-arginine induced epicardial artery dilatation in
patients with coronary artery disease—may be explained by
increased nitric oxide production in endothelial cells through
both increased eNOS substrate L-arginine and depressed
oxidative uncoupling of eNOS. Furthermore, vitamin C protects
nitric oxide from oxidative modification to peroxynitrite,
leading to a further increase in nitric oxide bioavailability. We
also observed greater reactivity in distal than in proximal
segments. This may be due to differences between proximal and
distal segments in smooth muscle density, endothelial function,
and vasomotor response to vasoactive stimuli.

Conclusions
Our results showed that L-arginine dependent coronary
segment vasodilatation by the antioxidant vitamin C is
augmented in patients with atherosclerosis, implying a
synergistic action of this combination on nitric oxide
bioactivity.

Authors’ affiliations
D Tousoulis*, C Xenakis*, C Tentolouris, C Antoniades, C Stefanadis,
Cardiology Unit, Hippokration Hospital, Athens University Medical
School, Athens, Greece
G Davies, T Crake, Hammersmith Hospital, London, UK

*These authors equally contributed in the study

Figure 2 Graphs showing mean (SEM) luminal diameter percentage changes from baseline of proximal and distal segments after infusion of normal saline, L-arginine, combined factors (group A: L-arginine and vitamin C; group B: L-arginine and NS; group C: vitamin C and NS), and nitrates. 

Distal segments dilated more than proximal segments (*p < 0.01).
REFERENCES

11th European Forum on Quality Improvement in Health Care
26–28 April 2006, Prague, Czech Republic
For further information please go to: www.quality.bmjg.com
Book early to benefit from a discounted delegate rate

www.heartjnl.com
Effects of vitamin C on intracoronary l-arginine dependent coronary vasodilatation in patients with stable angina

D Tousoulis, C Xenakis, C Tentolouris, G Davies, C Antoniades, T Crake and C Stefanadis

*Heart* 2005 91: 1319-1323
doi: 10.1136/hrt.2004.044537

Updated information and services can be found at:
http://heart.bmj.com/content/91/10/1319

These include:

**References**
This article cites 34 articles, 19 of which you can access for free at:
http://heart.bmj.com/content/91/10/1319#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Drugs: cardiovascular system (8842)
- Clinical diagnostic tests (4779)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/